Division of Valeant Pharmaceuticals International Inc.
Latest From Dermik Laboratories
Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Valeant Pharmaceuticals International Inc.
- Senior Management
- Contact Info
55 Corporate Dr.
Bridgewater, NJ 08807
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.